Immunomodulators in the Treatment of Atherosclerosis and Other Chronic Heart Diseases: Prospects and Risks.

Key Points

• Immunosuppressive therapy safety profiles remain critical for monitoring infectious complications and oncological risks.
• Decade-long surveillance across diverse populations is essential for understanding long-term impacts.
• Safety assessments focus on atherogenesis and its relation to chronic heart diseases, revealing emerging risks.
• Long-term studies can inform best practices and guide future research directions in chronic conditions.

Abstract